{
  "@context": "https://frontierpicks.com/schemas/dossier.v1.json",
  "ticker": "ONC",
  "name": "BeOne Medicines Ltd.",
  "url": "https://frontierpicks.com/dossiers/ONC/",
  "json_url": "https://frontierpicks.com/dossiers/ONC.json",
  "status": "DORMANT",
  "current_conviction": "MEDIUM",
  "graded_conviction": null,
  "archetype": {
    "code": "a1",
    "n": 1
  },
  "current_thesis": "Q2 print resolved bullish — revenue $1.705B vs $1.591B est., non-GAAP EPS/ADS $3.84 vs $1.44, FY26 guide raised to $6.6–6.8B — but the stock is still 7.9% under the $377.47 52-week high and the 2026-08-06 target wave was increments, not re-rates. Franchise compounding intact; the narrative is maturing with an empty 30-day calendar.",
  "invalidation_trigger": "A weekly close below $315 retraces the entire post-Q2 advance and loses the late-July shelf near $326; secondary: BRUKINSA US growth printing below the mid-20s% YoY at the Q3 report (vs +31% in Q2), or the FY26 guide merely reaffirmed at $6.6–6.8B.",
  "catalyst_date": null,
  "outcome": "OPEN",
  "outcome_date": null,
  "invalidation_fired": null,
  "themes": [
    "oncology-immunology",
    "precision-biotech-therapeutics"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "Redomiciled to Switzerland; BeiGene became BeOne Medicines and the Nasdaq ticker moved BGNE to ONC. Pre-2026 filings and data series appear under BGNE.",
    "Results are reported in US GAAP with EPS quoted per American Depositary Share; per-ADS figures are not comparable to the ordinary-share lines in the non-US listings.",
    "A half-year interim report with a US-GAAP-to-IFRS reconciliation is due on or before 2026-08-31 as a non-US listing requirement of the Swiss domicile.",
    "A CNY446M (~$62M) China tax settlement was disclosed 2026-06-26 as a Q2 2026 GAAP item; published Q2 summaries do not break out the line separately."
  ],
  "body_markdown": "## Current Thesis\nThe binary that gated this name resolved on 2026-08-05, and it resolved up: Q2 revenue $1.705B against $1.591B consensus, non-GAAP diluted EPS per ADS $3.84 against $1.44, and a full-year 2026 revenue guide lifted to $6.6–6.8B from $6.3–6.5B. The fundamental leg an investor is buying is intact — US BRUKINSA volume compounding at 31% YoY on the highest sustained new-patient starts since launch, with gross margin at 90% and GAAP operating income at $325M versus $88M a year earlier. What has changed is the *flow*. The July repricing wave (Jefferies upgrade to Buy, JPM $425, RBC $451) was a re-rate; the 2026-08-06 wave was arithmetic — Truist $416→$418, Citizens $396→$405, RBC $451→$450 lower — and the stock did not take out its high on a beat-and-raise. The 2026-08-14 close of $347.48 sits 7.9% below the split/dividend-adjusted 52-week high of $377.47. The narrative is **maturing** — well known, still working, moderating flow, with no dated company event inside 30 days to force the next leg.\n\n## Bull Case\n- Q2 2026 (2026-08-05): total revenue $1.705B vs $1.591B consensus, +30% YoY; non-GAAP diluted EPS/ADS $3.84 vs $1.44 consensus; GAAP diluted EPS/ADS $2.05, +144% YoY.\n- BRUKINSA global Q2 revenue $1.25B, +31% YoY; US sales $893M, +31%, attributed by the company to the highest level of sustained new-patient starts since launch. The US deceleration flagged as the fundamental crack ahead of the print did not appear.\n- FY2026 guidance raised for the second consecutive quarter: $6.3–6.5B (2026-05-06) → $6.6–6.8B (2026-08-05), against a $6.479B consensus. GAAP operating income guided $1.0–1.1B, non-GAAP $1.7–1.8B.\n- Operating leverage is showing in cash, not just non-GAAP: Q2 gross margin 90% vs 87% YoY, operating cash flow $463M vs $264M, free cash flow $435M vs $220M.\n- Second commercial product landed 2026-05-13: FDA accelerated approval of BEQALZI (sonrotoclax) in relapsed/refractory mantle-cell lymphoma after ≥2 prior lines including a BTK inhibitor — ORR 52%, median duration of response 15.8 months across 103 patients in BGB-11417-201. First BCL-2 inhibitor approved in MCL.\n- 2026-08-10 Revolution Medicines agreement: exclusive development and commercialization rights to four clinical-stage RAS(ON) inhibitors (daraxonrasib, elironrasib, zoldonrasib, RMC-5127) across selected Asian markets excluding Japan and South Korea, plus combination studies pairing BeOne's PRMT5 inhibitor BGB-58067 and trispecific BG-T187 with daraxonrasib or zoldonrasib. Extends the story past heme into RAS-addicted solid tumours.\n- Non-BRUKINSA lines are growing: TEVIMBRA $229M (+18% YoY), Europe revenue $208M (+37%), in-licensed/other $204M (+28%) in Q2.\n\n## Bear Case\n- A beat-and-raise of that size did not produce a new high. Nine trading days later the 2026-08-14 close of $347.48 was still 7.9% under the $377.47 adjusted-series 52-week high. When the best available news does not clear the prior peak, the marginal buyer is already accounted for.\n- The 2026-08-06 price-target cluster was incremental — TD Cowen $454, RBC $450 (cut from $451), Guggenheim $430, Truist $418 (from $416), Citizens $405 (from $396). Sell-side is nudging targets to keep pace with price rather than re-rating the franchise.\n- Frontline CLL, the largest prize for the BRUKINSA + sonrotoclax combination, has a crack: trade coverage (oncologypipeline.com / ApexOnco) reports CELESTIAL-301 did not demonstrate statistical superiority on the uMRD endpoint versus venetoclax + obinutuzumab, with the independent data-monitoring committee recommending continuation to the PFS primary endpoint. The announcement date was not confirmed in the sources retrieved here; the PFS readout is the resolving event.\n- The Revolution Medicines structure has BeOne funding and running a global registrational Phase 3 for a partner asset. That is real spend against the $1.7–1.8B non-GAAP operating income guide; economics of the deal were not disclosed in the summaries retrieved.\n- Calquence (AstraZeneca) remains the other share-taker into the Imbruvica cliff. The Q2 print showed BRUKINSA winning, not the war being over.\n- A CNY446M (~$62M) China tax settlement disclosed 2026-06-26 was flagged as a Q2 GAAP item; the retrieved Q2 summaries do not break out its line, so its drag on the $2.05 GAAP figure is not separately verifiable from here.\n\n## Setup & Price Structure\n- Reference close 2026-08-14: $347.48. RSI(14) 63.7 — momentum without an overbought extension. Three-month return +18.5%. Distance from the adjusted-series 52-week high $377.47: −7.9%.\n- The pre-print consolidation shelf sat near $326 (2026-07-24 close $325.90). The post-print advance has held above that shelf, which makes it the structural reference for the whole August leg.\n- The 2026-08-06 target band runs $405–454, entirely above the 2026-08-14 close. Every covering analyst in the recent feed is positioned constructive; there is no contrarian cushion if a franchise number disappoints.\n- Crowding observables, stated as observables: eleven price-target actions clustered between 2026-07-01 and 2026-08-06; no earnings date inside the next 30 days; low index beta (0.49 per prior coverage) so this grinds rather than gaps; RSI in the low 60s rather than the 80s. The filing feed for this window returned no Form 4 activity — that is absence of data, not evidence that no insider sold.\n- The gap between the last close and $377.47 is the measurable objective. A reclaim of that level on expanding volume would date a re-acceleration; failure to reclaim it while new targets keep printing is what a saturating narrative looks like.\n\n## Catalyst Calendar (next 30 days)\n\n- ~2026-08-31 (est.): half-year interim report with US-GAAP-to-IFRS reconciliation, a non-US listing / Swiss-domicile requirement. Low incremental information after the 2026-08-05 US-GAAP release; only matters if reconciled figures or segment detail diverge.\n- By 2026-12-31 (company target): Phase 3 starts for the GPC3 x 4-1BB bispecific and the B7-H4 ADC.\n- Q3 2026 results: early November, date not yet announced — outside the 30-day window. The calendar between now and then is genuinely thin, which is itself the near-term condition.\n\n## Elapsed catalysts\n\n- H2 2026, no date published (from the 2026-08-05 Q2 milestone slides): tacabrutideg Phase 2 data in relapsed/refractory CLL with a potential accelerated-approval submission; MANGROVE interim analysis and submission readiness in frontline MCL; TEVIMBRA Phase 3 data in first-line HER2+ gastroesophageal adenocarcinoma. Any could land inside the window unannounced; none carries a published date. *(passed 21d ago)*\n\n## What Would Change Our Mind\nThe structure that matters is the late-July shelf near $326 that the August advance was built on; losing it means the post-print re-rate was fully retraced by sellers who had the beat in hand. In price terms, a weekly close below $315 breaks that leg. On fundamentals, the number to watch is BRUKINSA US growth: +31% YoY in Q2 is what the multiple is paying for, and a Q3 print below the mid-20s% would flip the franchise story from share capture to maturation. A guide merely reaffirmed at $6.6–6.8B — after February's $6.2–6.4B, May's $6.3–6.5B and August's raise — ends the ratchet that has driven the target band higher. On the pipeline, a CELESTIAL-301 PFS readout without superiority would cap sonrotoclax near its R/R MCL label and remove the frontline-CLL leg entirely. And the theme flips to saturated if the next sell-side wave arrives as $450+ targets with no estimate revisions while price stays under $377.47.\n\n## Correlation Notes\n- Beta near 0.49 (prior coverage figure) means index direction explains little here; the name trades on franchise data and label news. Drawdowns in high-multiple growth do not automatically transmit.\n- Direct read-across pairs: AstraZeneca (Calquence, the competing BTK share-taker), AbbVie and J&J (Imbruvica's 2026 US/EU patent cliff, the share pool being redistributed), AbbVie/Roche (Venclexta, the incumbent sonrotoclax is attacking), and — new since 2026-08-10 — Revolution Medicines, whose shares rose on the announcement of the BeOne-funded Phase 3.\n- Policy correlation runs through US-China pharma exposure and drug-tariff headlines. The 2026-07-23 $300M New Jersey R&D/manufacturing expansion, taking total US manufacturing investment past $1B, is the company's explicit hedge against that channel.\n- Against XBI, the profitability profile (90% gross margin, $435M free cash flow in Q2) argues this trades closer to large-cap pharma than to the unprofitable-biotech complex; correlation to rate-sensitive biotech beta should be looser than the sector label implies.",
  "first_seen": "2026-07-26",
  "last_analyzed": "2026-08-16T15:43:36+00:00",
  "last_synthesized": "2026-08-16",
  "last_update_source": "watchlist_research",
  "license": "Content © FrontierPicks. Cite the canonical URL."
}